Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology.

If approved, the RLT could become a competitor to Novartis' Lutathera (177Lu-oxodotreotide). It has been awarded breakthrough status from the US FDA as a treatment for gastroenteropancreatic NETs.

Täglich aktuelle Solarnews zu den Themen Strom, Wärme, Mobilität - u.a. Photovoltaik und Solarthermie. Fundierte Hintergrundinformationen helfen den Überblick zu behalten!